Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1.

Boelen L, Debebe B, Silveira M, Salam A, Makinde J, Roberts CH, Wang ECY, Frater J, Gilmour J, Twigger K, Ladell K, Miners KL, Jayaraman J, Traherne JA, Price DA, Qi Y, Martin MP, Macallan DC, Thio CL, Astemborski J, Kirk G, Donfield SM, Buchbinder S, Khakoo SI, Goedert JJ, Trowsdale J, Carrington M, Kollnberger S, Asquith B.

Sci Immunol. 2018 Nov 9;3(29). pii: eaao2892. doi: 10.1126/sciimmunol.aao2892.

PMID:
30413420
2.

HIV/HCV Co-infection, Liver Disease Progression, and Age-Related IGF-1 Decline.

Quinn J, Astemborski J, Mehta SH, Kirk GD, Thomas DL, Balagopal A.

Pathog Immun. 2017;2(1):50-59. doi: 10.20411/pai.v2i1.183. Epub 2017 Mar 3.

3.

Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study.

Cepeda JA, Thomas DL, Astemborski J, Sulkowski MS, Kirk GD, Mehta SH.

Clin Infect Dis. 2017 Jul 15;65(2):235-243. doi: 10.1093/cid/cix207.

4.

Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection.

Veenhuis RT, Astemborski J, Chattergoon MA, Greenwood P, Jarosinski M, Moore RD, Mehta SH, Cox AL.

Clin Infect Dis. 2017 Mar 1;64(5):589-596. doi: 10.1093/cid/ciw771. Epub 2016 Dec 7.

5.

Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection.

Patel EU, Cox AL, Mehta SH, Boon D, Mullis CE, Astemborski J, Osburn WO, Quinn J, Redd AD, Kirk GD, Thomas DL, Quinn TC, Laeyendecker O.

J Infect Dis. 2016 Aug 1;214(3):344-52. doi: 10.1093/infdis/jiw005. Epub 2016 Jan 14.

6.

HIV Infection Is Associated With Increased Risk for Acute Exacerbation of COPD.

Lambert AA, Kirk GD, Astemborski J, Mehta SH, Wise RA, Drummond MB.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):68-74. doi: 10.1097/QAI.0000000000000552.

7.

Incarceration and injection drug use in Baltimore, Maryland.

Genberg BL, Astemborski J, Vlahov D, Kirk GD, Mehta SH.

Addiction. 2015 Jul;110(7):1152-9. doi: 10.1111/add.12938. Epub 2015 May 7.

8.

The relationship of physical performance with HIV disease and mortality.

Greene M, Covinsky K, Astemborski J, Piggott DA, Brown T, Leng S, Galai N, Mehta SH, Guralnik J, Patel KV, Kirk GD.

AIDS. 2014 Nov 28;28(18):2711-9. doi: 10.1097/QAD.0000000000000507.

9.

A randomized study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users.

Drummond MB, Astemborski J, Lambert AA, Goldberg S, Stitzer ML, Merlo CA, Rand CS, Wise RA, Kirk GD.

BMC Public Health. 2014 Jul 28;14:761. doi: 10.1186/1471-2458-14-761.

10.

A cross sectional analysis of the role of the antimicrobial peptide cathelicidin in lung function impairment within the ALIVE cohort.

Lambert AA, Kirk GD, Astemborski J, Neptune ER, Mehta SH, Wise RA, Drummond MB.

PLoS One. 2014 Apr 17;9(4):e95099. doi: 10.1371/journal.pone.0095099. eCollection 2014.

11.

Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland.

Genberg BL, Gillespie M, Schuster CR, Johanson CE, Astemborski J, Kirk GD, Vlahov D, Mehta SH.

Addict Behav. 2013 Dec;38(12):2868-73. doi: 10.1016/j.addbeh.2013.08.008. Epub 2013 Aug 17.

12.

Variants in HAVCR1 gene region contribute to hepatitis C persistence in African Americans.

Wojcik G, Latanich R, Mosbruger T, Astemborski J, Kirk GD, Mehta SH, Goedert JJ, Kim AY, Seaberg EC, Busch M, Thomas DL, Duggal P, Thio CL.

J Infect Dis. 2014 Feb 1;209(3):355-9. doi: 10.1093/infdis/jit444. Epub 2013 Aug 20.

13.

Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.

Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O'Brien TR.

J Infect Dis. 2014 Feb 1;209(3):350-4. doi: 10.1093/infdis/jit433. Epub 2013 Aug 15.

14.

Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users.

Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD.

AIDS. 2013 Oct 23;27(16):2559-66. doi: 10.1097/QAD.0b013e328363bff2.

15.

HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study.

Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, Balagopal A, Thomas DL.

Ann Intern Med. 2013 May 7;158(9):658-66. doi: 10.7326/0003-4819-158-9-201305070-00604.

16.

The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort.

Drummond MB, Merlo CA, Astemborski J, Kalmin MM, Kisalu A, Mcdyer JF, Mehta SH, Brown RH, Wise RA, Kirk GD.

AIDS. 2013 May 15;27(8):1303-11. doi: 10.1097/QAD.0b013e32835e395d.

17.

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR.

Nat Genet. 2013 Feb;45(2):164-71. doi: 10.1038/ng.2521. Epub 2013 Jan 6.

18.

HIV incidence determination in the United States: a multiassay approach.

Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Mehta SH, Astemborski J, Jacobson LP, Margolick JB, Brown J, Quinn TC, Eshleman SH.

J Infect Dis. 2013 Jan 15;207(2):232-9. doi: 10.1093/infdis/jis659. Epub 2012 Nov 5.

19.

Stability of liver fibrosis among HCV-infected injection drug users.

Mehta SH, Kirk GD, Astemborski J, Sulkowski MS, Afdhal NH, Thomas DL.

Antivir Ther. 2012;17(5):813-21. doi: 10.3851/IMP2085. Epub 2012 Mar 15.

20.

Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users.

Munshaw S, Hwang HS, Torbenson M, Quinn J, Hansen KD, Astemborski J, Mehta SH, Ray SC, Thomas DL, Balagopal A.

Hepatology. 2012 Aug;56(2):544-54. doi: 10.1002/hep.25655. Epub 2012 Jul 6.

21.

Association between obstructive lung disease and markers of HIV infection in a high-risk cohort.

Drummond MB, Kirk GD, Astemborski J, Marshall MM, Mehta SH, McDyer JF, Brown RH, Wise RA, Merlo CA.

Thorax. 2012 Apr;67(4):309-14. doi: 10.1136/thoraxjnl-2011-200702. Epub 2011 Nov 16.

22.

KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection.

Seich Al Basatena NK, Macnamara A, Vine AM, Thio CL, Astemborski J, Usuku K, Osame M, Kirk GD, Donfield SM, Goedert JJ, Bangham CR, Carrington M, Khakoo SI, Asquith B.

PLoS Pathog. 2011 Oct;7(10):e1002270. doi: 10.1371/journal.ppat.1002270. Epub 2011 Oct 13.

23.

Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort.

Kurbanov F, Abdel-Hamid M, Latanich R, Astemborski J, Mohamed M, Mikhail NM, El-Daly M, El-Kafrawy S, Thomas DL, Thio CL.

J Infect Dis. 2011 Nov;204(9):1391-4. doi: 10.1093/infdis/jir536. Epub 2011 Sep 20.

24.

Correlates of non-medical prescription drug use among a cohort of injection drug users in Baltimore City.

Khosla N, Juon HS, Kirk GD, Astemborski J, Mehta SH.

Addict Behav. 2011 Dec;36(12):1282-7. doi: 10.1016/j.addbeh.2011.07.046. Epub 2011 Aug 5.

25.

CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C.

Zeremski M, Dimova R, Astemborski J, Thomas DL, Talal AH.

J Infect Dis. 2011 Sep 15;204(6):832-6. doi: 10.1093/infdis/jir424.

26.

Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis.

Bacchetti P, Boylan R, Astemborski J, Shen H, Mehta SH, Thomas DL, Terrault NA, Monto A.

PLoS One. 2011;6(5):e20104. doi: 10.1371/journal.pone.0020104. Epub 2011 May 27.

27.

Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users.

Drummond MB, Kirk GD, Astemborski J, McCormack MC, Marshall MM, Mehta SH, Wise RA, Merlo CA.

Int J Chron Obstruct Pulmon Dis. 2011;6:89-95. doi: 10.2147/COPD.S15968. Epub 2011 Jan 19.

28.

Changes in blood-borne infection risk among injection drug users.

Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, Thomas DL.

J Infect Dis. 2011 Mar 1;203(5):587-94. doi: 10.1093/infdis/jiq112. Epub 2011 Jan 31.

29.

Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors.

Salgado M, Kirk GD, Cox A, Rutebemberwa A, Higgins Y, Astemborski J, Thomas DL, Thio CL, Sulkowski MS, Blankson JN.

AIDS. 2011 Jan 28;25(3):385-7. doi: 10.1097/QAD.0b013e328341b86a.

30.

Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008.

Mehta SH, Kirk GD, Astemborski J, Galai N, Celentano DD.

Clin Infect Dis. 2010 Jun 15;50(12):1664-71. doi: 10.1086/652867.

31.

Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.

Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC.

J Virol. 2010 May;84(10):5067-77. doi: 10.1128/JVI.02265-09. Epub 2010 Mar 3.

32.

Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.

Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, Higgins Y, Moore RD, Afdhal N, Torbenson M, Sulkowski M, Thomas DL.

Clin Infect Dis. 2009 Apr 1;48(7):963-72. doi: 10.1086/597350.

33.

Nonstructured treatment interruptions among injection drug users in Baltimore, MD.

Kavasery R, Galai N, Astemborski J, Lucas GM, Celentano DD, Kirk GD, Mehta SH.

J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):360-6. doi: 10.1097/QAI.0b013e318198a800.

34.

High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection.

Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA, Clute S, Wang C, Korman A, Sette A, Sidney J, Pardoll DM, Cox AL.

J Immunol. 2008 Dec 15;181(12):8215-25.

35.

Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B.

Thio CL, Astemborski J, Thomas R, Mosbruger T, Witt MD, Goedert JJ, Hoots K, Winkler C, Thomas DL, Carrington M.

J Immunol. 2008 Dec 1;181(11):7944-7.

36.

Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users.

Golub JE, Astemborski J, Ahmed M, Cronin W, Mehta SH, Kirk GD, Vlahov D, Chaisson RE.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):532-7. doi: 10.1097/QAI.0b013e31818d5c1c.

37.

Low frequency of GB virus C viremia in a cohort of HIV-1-infected elite suppressors.

Blankson JN, Klinzman D, Astemborski J, Thomas DL, Kirk GD, Stapleton JT.

AIDS. 2008 Nov 12;22(17):2398-400. doi: 10.1097/QAD.0b013e328316c3fb.

PMID:
18981782
38.

Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.

Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, Kirk GD, Mehta SH, Cox AL, Thomas DL, Ray SC.

Gastroenterology. 2008 Jul;135(1):226-33. doi: 10.1053/j.gastro.2008.03.022. Epub 2008 Mar 29.

39.

Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2.

Pandey JP, Luo Y, Elston RC, Wu Y, Philp FH, Astemborski J, Thomas DL, Netski DM.

Hum Immunol. 2008 Mar;69(3):158-64. doi: 10.1016/j.humimm.2008.01.019. Epub 2008 Mar 10.

40.

Limited uptake of hepatitis C treatment among injection drug users.

Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL.

J Community Health. 2008 Jun;33(3):126-33. doi: 10.1007/s10900-007-9083-3.

41.
42.

Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution.

Wang XH, Netski DM, Astemborski J, Mehta SH, Torbenson MS, Thomas DL, Ray SC.

J Virol. 2007 Jun;81(12):6513-22. Epub 2007 Feb 28.

43.

CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection.

Netski DM, Mosbruger T, Astemborski J, Mehta SH, Thomas DL, Cox AL.

J Infect Dis. 2007 Mar 15;195(6):857-63. Epub 2007 Feb 7.

PMID:
17299716
44.

Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.

Thio CL, Astemborski J, Bashirova A, Mosbruger T, Greer S, Witt MD, Goedert JJ, Hilgartner M, Majeske A, O'Brien SJ, Thomas DL, Carrington M.

J Virol. 2007 Jan;81(2):441-5. Epub 2006 Nov 1.

45.

HIV incidence among injection drug users in Baltimore, Maryland (1988-2004).

Mehta SH, Galai N, Astemborski J, Celentano DD, Strathdee SA, Vlahov D, Nelson KE.

J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):368-72.

PMID:
16980912
46.

Progression of liver fibrosis among injection drug users with chronic hepatitis C.

Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL.

Hepatology. 2006 Apr;43(4):788-95.

PMID:
16557548
47.

Serum albumin as a prognostic indicator for HIV disease progression.

Mehta SH, Astemborski J, Sterling TR, Thomas DL, Vlahov D.

AIDS Res Hum Retroviruses. 2006 Jan;22(1):14-21.

PMID:
16438640
48.

Mannose binding lectin genotypes influence recovery from hepatitis B virus infection.

Thio CL, Mosbruger T, Astemborski J, Greer S, Kirk GD, O'Brien SJ, Thomas DL.

J Virol. 2005 Jul;79(14):9192-6.

49.

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH.

J Hepatol. 2005 Jul;43(1):78-84. Epub 2005 Apr 25.

PMID:
15894397
50.

Sex-based differences in T lymphocyte responses in HIV-1-seropositive individuals.

Sterling TR, Pisell-Noland T, Perez JL, Astemborski J, McGriff JR, Nutting L, Hoover DR, Vlahov D, Bollinger RC.

J Infect Dis. 2005 Mar 15;191(6):881-5. Epub 2005 Feb 7.

PMID:
15717262

Supplemental Content

Loading ...
Support Center